Targeted therapies for gynecologic malignancies.
Despite the enormous promise that targeted therapies hold for patients with gynecologic malignancies, it is far too early to recommend any targeted therapy outside of a clinical trial. There remains considerable work to be done before targeted therapies will have a significant role in this patient population. We have learned that different tumor types express different targets, but that the mere expression of a target does not necessarily correlate with benefit from the use of the targeted agent. No less important is the challenge of determining how these agents should be studied in clinical trials, and what constitutes an active agent. To document efficacy, targeted agents would hopefully produce response (ie, shrinkage of measurable tumor), but as cytostatic agents, the ability to delay tumor growth or slow the development of symptoms would be clinically important. Combining targeted therapies with cytotoxic agents, radiation, or other targeted therapies may be important areas for study, but it is essential to demonstrate the additive or synergistic effect of the targeted therapy to an already established active one. This review covers strategies used to develop targeted agents, reviews available targeted therapies, and suggests potential roles in the treatment of gynecologic cancers.
Hyde
Johnny
J
University of Oklahoma- HSC, PO Box 26901, Oklahoma City, OK 73190, USA.
McMeekin
D Scott
DS
D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D006801:Humans; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis; D011878:Radiotherapy; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
D066246:ErbB Receptors
Lancet. 2004 May 29;363(9423):1802-11
15172781
J Clin Oncol. 2004 Mar 1;22(5):777-84
14990632
Gynecol Oncol. 1997 Aug;66(2):250-4
9264571
Int J Gynecol Pathol. 1997 Jul;16(3):256-62
9421092
Gynecol Oncol. 1996 Aug;62(2):278-81
8751561
Clin Cancer Res. 2000 May;6(5):2053-63
10815932
J Clin Oncol. 2003 Jun 15;21(12):2237-46
12748244
JAMA. 2003 Oct 22;290(16):2149-58
14570950
Am J Clin Oncol. 2003 Oct;26(5):e150-6
14528090
Gynecol Oncol. 2004 Oct;95(1):32-6
15385107
Cancer Res. 2001 Mar 15;61(6):2420-3
11289108
Br J Cancer. 1996 Feb;73(3):301-6
8562334
J Natl Cancer Inst. 1998 Mar 18;90(6):447-54
9521169
Br J Cancer. 2004 Aug 2;91(3):418-24
15238978
J Clin Oncol. 2002 Feb 15;20(4):1147-9
11844842
Cancer Treat Rev. 2003 May;29 Suppl 1:33-9
12738241
J Clin Oncol. 2004 Jun 1;22(11):2184-91
15169807
J Clin Oncol. 2002 Nov 15;20(22):4478-84
12431972
J Reprod Med. 2004 Feb;49(2):71-5
15018431
Ann Pharmacother. 2004 Jul-Aug;38(7-8):1258-64
15187215
J Clin Oncol. 2004 Mar 1;22(5):785-94
14990633
Clin Cancer Res. 1999 Mar;5(3):577-86
10100709
Oncogene. 2003 Sep 29;22(42):6570-8
14528282
Semin Oncol. 2003 Feb;30(1 Suppl 1):21-9
12644981
Ann Oncol. 1998 Oct;9(10):1047-52
9834816
J Clin Oncol. 2003 Jan 15;21(2):283-90
12525520
J Clin Pharm Ther. 2004 Apr;29(2):95-103
15068398
N Engl J Med. 2002 Feb 28;346(9):683-93
11870247
Oncologist. 2002;7(5):401-9
12401902
N Engl J Med. 1999 Nov 18;341(21):1565-71
10564685
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
Tumour Biol. 2000 Nov-Dec;21(6):358-66
11006576
J Clin Oncol. 2001 Jul 1;19(13):3234-43
11432891
J Clin Oncol. 2003 Jan 1;21(1):60-5
12506171
N Engl J Med. 2001 Mar 15;344(11):783-92
11248153
J Clin Oncol. 1999 Sep;17(9):2639-48
10561337
J Clin Oncol. 2004 Apr 1;22(7):1180-7
14981103
J Clin Oncol. 2004 Aug 1;22(15):3126-32
15284264
Oncologist. 2004;9(4):357-60
15266089
Cancer Res. 1993 Oct 1;53(19):4550-4
8402626
Gynecol Oncol. 2003 Mar;88(3):263-5
12648572
Semin Radiat Oncol. 2003 Oct;13(4):454-68
14586834
Clin Cancer Res. 2001 May;7(5):1204-13
11350885